BLFS:NSD-BioLife Solutions Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 46.94

Change

0.00 (0.00)%

Market Cap

USD 1.94B

Volume

0.24M

Avg Analyst Target

USD 63.00 (+34.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington. Address: 3303 Monte Villa Parkway, Bothell, WA, United States, 98021

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

N/A

USD124.15B 77.90 60.83
HOLX Hologic Inc

N/A

USD19.39B 9.80 7.22
RGEN Repligen Corporation

N/A

USD17.77B 179.69 106.78
MASI Masimo Corporation

N/A

USD15.61B 73.44 50.02
NVCR NovoCure Limited

N/A

USD13.19B 1,480.87 528.28
XRAY DENTSPLY SIRONA Inc

N/A

USD13.12B 35.81 17.08
STAA STAAR Surgical Company

N/A

USD6.76B 349.39 213.03
ICUI ICU Medical Inc

N/A

USD5.15B 51.02 21.45
MMSI Merit Medical Systems Inc

N/A

USD4.07B 144.52 31.03
ATRC AtriCure Inc

N/A

USD3.29B N/A N/A

ETFs Containing BLFS

Symbol Name Weight Mer Price(Change) Market Cap
XHE SPDR Series Trust - SPDR .. 0.00 % 0.35 %

N/A

USD0.81B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.67% 67% D+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.67% 67% D+ 64% D
Trailing 12 Months  
Capital Gain 78.82% 77% C+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.82% 77% C+ 75% C
Trailing 5 Years  
Capital Gain 2,410.29% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,410.29% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 136.65% 97% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.65% 97% A+ 95% A
Risk Return Profile  
Volatility (Standard Deviation) 126.45% 13% F 12% F
Risk Adjusted Return 108.07% 77% C+ 95% A
Market Capitalization 1.94B 67% D+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 411.75 9% F 3% F
Price/Book Ratio 4.33 58% F 33% F
Price / Cash Flow Ratio 297.06 6% F 2% F
EV/EBITDA 998.07 5% F 1% F
Management Effectiveness  
Return on Equity 1.25% 52% F 54% F
Return on Invested Capital -0.05% 52% F 52% F
Return on Assets -1.00% 44% F 42% F
Debt to Equity Ratio 0.32% 89% B+ 90% A-
Technical Ratios  
Short Ratio 3.45 61% D- 48% F
Short Percent 8.61% 9% F 21% F
Beta 1.41 35% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.